Gene:
CBL
Cbl proto-oncogene, E3 ubiquitin protein ligase

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  CBL2; oncogene CBL2
Alternate Symbols:  RNF55; c-Cbl
PharmGKB Accession Id: PA26115

Details

Cytogenetic Location: chr11 : q23.3 - q23.3
GP mRNA Boundary: chr11 : 119076986 - 119178859
GP Gene Boundary: chr11 : 119066986 - 119181859
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Publications related to CBL: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population. Annals of laboratory medicine. 2015. Park Sang Hyuk, et al. PubMed

LinkOuts

NCBI Gene:
867
OMIM:
165360
UCSC Genome Browser:
NM_005188
RefSeq RNA:
NM_005188
RefSeq Protein:
NP_005179
RefSeq DNA:
NG_016808
NT_033899
UniProtKB:
CBL_HUMAN (P22681)
Ensembl:
ENSG00000110395
GenAtlas:
CBL
GeneCard:
CBL
MutDB:
CBL
ALFRED:
LO029561X
HuGE:
CBL
Comparative Toxicogenomics Database:
867
ModBase:
P22681
HumanCyc Gene:
HS03306
HGNC:
1541

Common Searches